Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma

Haematologica

Volumn 86, Issue 3, 2001, Pages 274-281

  Vassilakopoulos, T P ^a   Nadali, G ^a   Angelopoulou, M K ^a   Siakantaris, M P ^a   Dimopoulou, M N ^a   Kontopidou, F N ^a   Rassidakis, G Z ^a   Doussis Anagnostopoulou, I A ^a   Hatzioannou, M ^a   Vaiopoulos, G ^a   Kittas, C ^a   Sarris, A H ^a   Pizzolo, G ^a   Pangalis, G A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Chemotherapy; Hodgkin's lymphoma; Interleukin 10; Prognostic factors; Serum levels

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; INTERLEUKIN 10; INTERLEUKIN 10 RECEPTOR; PROTEIN BCL 2; VINBLASTINE;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; REED STERNBERG CELL; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HODGKIN DISEASE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 0035074841     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP
2. Alternating drug combinations in the treatment of advanced Hodgkin's disease
3. MOPP/ABV hybrid program: Combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease
4. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
5. EBVD combination chemotherapy plus low dose involved field radiation is a highly effective treatment modality for early stage Hodgkin's disease
6. Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: Ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients
7. EBVP chemotherapy plus irradiation provides event-free survival (EFS) superior to subtotal nodal irradiation (STNI) in favorable clinical stage (CS) I-II Hodgkin's disease, but inferior to MOPP-ABV plus irradiation in unfavorable cases: The EORTC-GPMC H7 randomized trials
8. Subtotal nodal (STNI) vs. involved field (IFRT) irradiation after 4 cycles of ABVD in early stage Hodgkin's disease (HD)
9. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial
10. Treatment of advanced Hodgkin's disease with chemotherapy-comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada clinical trials group
11. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results
12. MOPP/ABV versus ABVD for advanced Hodgkin's disease - A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC)
13. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease
14. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy
15. A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosis. The Scotland and Newcastle Lymphoma Group (SNLG) Therapy Working Party
16. Prognosis of patients with advanced Hodgkin's disease: Evaluation of four prognostic models using 344 patients included in the Group d' Etudes des Lymphomes de l' Adulte Study
17. A prognostic model for advanced Hodgkin's disease at M.D. Anderson validated with an independent set of patients treated at Memorial Sloan-Kettering
18. A prognostic model for failure-free survival (FFS) of adults with clinical Ann Arbor stage (AAS) I or II Hodgkin's disease (HD) after combined modality therapy
19. A predictive model for failure-free survival (FFS) of adults with Hodgkin's disease (HD) treated with ABVD or equivalent regimens
20. Prognostic factors for advanced stage Hodgkin's disease (HD)
21. Soluble molecules as biological markers in Hodgkin's disease
22. Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome
23. Soluble cytokine levels correlate with the activity and clinical stage of Hodgkin's disease at diagnosis
24. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients
25. Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease
26. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease
27. Serum levels of circulating ICAM-1 are increased in Hodgkin's disease
28. The significance of serum levels of soluble 60kDa receptors for tumor necrosis factor in patients with Hodgkin's disease
29. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms
30. Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease
31. Circulating soluble ICAM-1 in patients with Hodgkin's disease
32. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease
33. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease
34. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival
35. Cytokine fusion-toxins show specific potency against Hodgkin lymphoma cells in vitro
36. + hematopoietic progenitor cells
37. IL-10 inhibits apoptotic cell death in human T cells starved of IL-2
38. Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells
39. Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes
40. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells
41. Clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells in Hodgkin's disease
42. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease
43. Report of the Committee on Hodgkin's Disease Staging Classification
44. Nonparametric estimation from incomplete observations
45. Evaluation of survival data and two new rank order statistics arising in its consideration
46. Regression models and life tables (with Discussion)
47. Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, the Milan Cancer Institute experience
48. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients?
49. Bcl-2 expression in Hodgkin-Reed-Sternberg cells (HRS) of patients with classical Hodgkin's disease is associated with lower progression-free survival and survival
50. Prognostic factors in Hodgkin's disease: Multivariate analysis of 327 patients from a single institution
51. Do biological markers add to prediction of outcome achieved by the international score in Hodgkin's disease?